Table 5.
Baseline characteristics of ZONDA patients before and after adjusting to LIBERTY ASTHMA VENTURE patients for the analysis of annual exacerbation rate
| Characteristics | ZONDAa (before adjusting) | LIBERTY ASTHMA VENTURE (aggregate reported data) | ZONDA (after adjusting to LIBERTY ASTHMA VENTURE) |
|---|---|---|---|
| Benralizumab 30 mg Q8W + placebo N = 148b | Dupilumab 300 mg Q2W + placebo N = 210 | Benralizumab 30 mg Q8W + placebo ESS = 36 | |
| BMI, kg/m2 | 29.47 (5.94) | 29.34 (5.96) | 29.34 (3.72) |
| ACQ‐5 score | 2.69 (1.15) | 2.50 (1.16) | 2.50 (0.72) |
| Mean number of exacerbations in previous year | 2.78 (2.36) | 2.09 (2.16) | 2.09 (1.35) |
| OCS dosage adjusted at baseline, prednisolone equivalent, mg/d | 14.21 (7.06) | 11.26 (6.12) | 11.26 (3.82) |
| Blood eosinophil count, cells/µL | 583.05 (478.99) | 347 (307) | 347 (191.48) |
| Nasal polyps (%) | 32.43 | 33.8 | 33.8 |
Data presented as mean (SD) unless otherwise indicated.
Abbreviations: ACQ‐5: Asthma Control Questionnaire 5; BMI: body mass index; ESS: effective sample size; OCS: oral corticosteroid; Q2W: every 2 wk; Q8W: every 8 wk (first three doses every 4 wk); SD: standard deviation.
a
Data for the ZONDA population are calculated from individual patient data.
b
One patient was missing a baseline blood eosinophil count.